Related Experiment Video
Updated: Aug 20, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Lymphocytes subsets in the course of continuous ambulatory peritoneal dialysis (CAPD)
Ioannis Griveas1, G Visvardis, A Fleva
1Nephrology Department, Papageorgiou General Hospital, Thessaloniki, Greece. giannisgriv@hotmail.com
Background:
We studied lymphocyte subset counts in comparison with normal subjects in order to clarify the abnormalities of cellular immune responses in uremic patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Methods:
The study included 37 CAPD patients and 45 normal individuals, as the control group. For the study, CAPD patients were divided into four groups depending on duration of replacement therapy. Group I consisted of patients treated for 0-6 months (n=6), group II for 6-12 months (n=6), group III for 13-24 months (n=16), and group IV for more than 25 months (n=9). Flow cytometry was used for estimation of lymphocyte subsets (determination of CD2, CD3, CD3+/CD4+, CD3+/CD8+, CD3-/16+56+, CD19, CD4/CD8).
Results:
Our patients started CAPD with decreased lymphocyte subset counts, slightly above the normal range (excluding CD3 -/16+56+, CD2). After 6 months of CAPD therapy, an increase in CD4/CD8 ratio was observed and all examined lymphocyte subset counts decreased (excluding CD2). In patients on CAPD for more than 25 months, CD3+/CD4+, CD19 counts were below the normal range, CD3 -/16+56+ exceeded the upper limit of normal range and at the same time mean total lymphocyte count (TLC) was maintained in the normal range.
Conclusions:
We recommend lymphocyte subset determinations for detection of immune abnormalities in the course of CAPD treatment.
Related Concept Videos
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal Dialysis I: Introduction and Procedure
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
